SEP 16·SEC EDGARLow
Dizon Romeo R purchased $5K of IRIX
Dizon Romeo R (Chief Financial Officer) purchased 7,900 shares of IRIDEX CORP (IRIX) at $0.63 on 2026-09-16.
StockNASDAQ · US · USDHealthcare · Medical Devices
$IRIX
IRIDEX CORP
AlphAI earnings readSecond quarter 2026 · AUG 18Iridex reported second-quarter revenue of $12.6 million, down 7%, as 19% Cyclo G6 growth was offset by lower retina sales; the company reaffirmed full-year revenue guidance of $51 million to $53 million.Verdict: mixedRead →
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Price · $IRIXvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $IRIX in the last 7 days.
Insider · 30dAll trades →
- Buys
- $15K 5 txs
- Sells
- — 0 txs
Dizon Romeo R5× · $15K
10b5-1 share of filings0%
Top stories · $IRIXMore →
SEP 14·SEC EDGAR
Dizon Romeo R purchased $2K of IRIX
Dizon Romeo R (Chief Financial Officer) purchased 2,354 shares of IRIDEX CORP (IRIX) at $0.65 on 2026-09-14.
SEP 10·SEC EDGAR
Dizon Romeo R purchased $3K of IRIX
Dizon Romeo R (Chief Financial Officer) purchased 5,100 shares of IRIDEX CORP (IRIX) at $0.68 on 2026-09-10.
IRIX sentiment & insider activity
Recent IRIX coverage spans earnings and insider activity.
In the last 30 days, IRIX insiders filed 5 SEC Form 4 transactions — 5 purchases ($15K) and no sales. The most active reporter was Dizon Romeo R, Chief Financial Officer, with 5 filings.
What's driving IRIX
Small insider buy by CFO; unlikely to move price materially.
Small insider purchase by CFO; unlikely to move price.
Insider purchase signals confidence from CFO, but size is negligible relative to float.
Earnings miss on revenue but positive cash flow and maintained guidance may limit downside.
Small insider purchase may signal confidence but limited market impact.
AlphAI scores every news story that mentions IRIX with an AI model for sentiment and relevance, and aggregates insider trades from IRIDEX CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $IRIX
Score
Dizon Romeo R purchased $5K of IRIX
Dizon Romeo R (Chief Financial Officer) purchased 7,900 shares of IRIDEX CORP (IRIX) at $0.63 on 2026-09-16.
1 min readDizon Romeo R purchased $2K of IRIX
Dizon Romeo R (Chief Financial Officer) purchased 2,354 shares of IRIDEX CORP (IRIX) at $0.65 on 2026-09-14.
1 min readDizon Romeo R purchased $3K of IRIX
Dizon Romeo R (Chief Financial Officer) purchased 5,100 shares of IRIDEX CORP (IRIX) at $0.68 on 2026-09-10.
1 min read
IRIDEX (IRIX) Q2 2026 Earnings Call Transcript
IRIDEX (IRIX) reported Q2 2026 revenue of $12.6M, down 7% YoY, with Cyclo G6 product revenue up 19% but retina revenue down. Net loss was $1.3M. Management maintained full-year revenue guidance of $51M-$53M, excluding Middle East revenue, and expects low-double-digit glaucoma growth and low-single-digit retina growth in H2 2026.
2 min readDizon Romeo R purchased $5K of IRIX
Dizon Romeo R (Chief Financial Officer) purchased 6,668 shares of IRIDEX CORP (IRIX) at an average of $0.75 ($0.75–$0.75) across 2 trades on 2026-08-24.
1 min readUS$2.75: That's What Analysts Think IRIDEX Corporation (NASDAQ:IRIX) Is Worth After Its Latest Results
IRIDEX Corporation (NASDAQ:IRIX) missed earnings expectations, with revenues of US$13m and a loss of US$0.07 per share. Analysts reduced the price target by 8.3% to US$2.75, citing increased loss expectations for 2026. Despite a forecasted 3.7% annual revenue growth, it lags behind the industry's 7.6% growth estimate.
2 min read
IRIDEX Corporation Q2 2026 Earnings Call Summary
IRIDEX Corporation reported positive cash flow in Q2 2026, driven by cost restructuring and working capital management. The company reaffirmed full-year revenue guidance of $51M-$53M, excluding Middle East revenue. Glaucoma probe volume increased 35%, while retina revenue declined due to temporary commercial transitions. Management expects retina growth to return in H2 2026 and PASCAL systems to secure European approval in H1 2027. Operating expenses decreased 5% year-over-year.
2 min readIridex Posts Q2 Results, Glaucoma Segment Shows Strength
Iridex (IRIX) reported Q2 2026 revenue of $12.6M, down 7% YoY, with retina sales declining but glaucoma product sales up 19%. Net loss was $1.3M, or $0.07 per share. The company reaffirmed its annual revenue guidance of $51M-$53M. CEO Patrick Mercer cited strong glaucoma momentum and restructuring efforts for long-term profitability.
2 min read
IRIDEX Corp (IRIX) (Q2 2026) Earnings Call Highlights: Cyclo-G6 Surges 35% as Company
IRIDEX Corp (IRIX) reported Q2 2026 earnings, highlighting a 35% surge in Cyclo-G6 probe sales. CEO Patrick Mercer expects low single-digit retina growth for the year, driven by regulatory approvals and promotions, despite headwinds in the Middle East and China. The company placed fewer Cyclo-G6 systems due to regulatory delays but anticipates higher numbers in Q4. Glaucoma growth was broad-based, with strong US and international performance. Revenue decline was attributed to retina business and
2 min readIRIDEX CORP (IRIX): Results of Operations and Financial Condition
IRIDEX CORP (IRIX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Iridex Reports Second Quarter 2026 Financial Results MOUNTAIN VIEW, Calif., August 18, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for
6 min read